Beta-adrenergic blockade and cardiac arrhythmias.

The evaluation of beta-adrenergic blockade in cardiac arrhythmias is difficult because of the complex nature of the arrhythmias and the varied modes of action of blocking drugs. Studies have confirmed the therapeutic value of the betaadrenergic blocking drug pronethalol (Alderlin) (Vaughan Williams, 1963 ; Stock and Dale, 1963 ; Payne and Senfield, 1964; Wolfson et al., 1966) and its more potent successor, propranolol (Inderal) in the management of many different atrial and ventricular arrhythmias (Harrison et al., 1965; Sloman et al., 1965 ; Stock, 1966; Harris, 1966; Szekely et al., 1966; Cherchi et al., 1966; Rochet and Vastesaeger, 1966; Gettes and Surawicz, 1966; Luria et al., 1966; Epstein and Braunwald, 1966). This study reports our experience in the management of patients with paroxysmal arrhythmias, acute life-threatening arrhythmias, and recurrent arrhythmias associated with prolonged cardiac arrest. An attempt has also been made to assess the prophylactic value of propranolol in reducing the high incidence of arrhythmias associated with acute myocardial infarction.